Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985904%3A_____%2F23%3A00580326" target="_blank" >RIV/67985904:_____/23:00580326 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/23:10471708 RIV/00216208:11110/23:10471708 RIV/00216208:11120/23:43926209 RIV/00064173:_____/23:43926209 RIV/00064203:_____/23:10471708
Result on the web
<a href="https://academic.oup.com/crohnscolitis360/article/5/4/otad040/7231024?login=true" target="_blank" >https://academic.oup.com/crohnscolitis360/article/5/4/otad040/7231024?login=true</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/crocol/otad040" target="_blank" >10.1093/crocol/otad040</a>
Alternative languages
Result language
angličtina
Original language name
Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?
Original language description
Background A subcutaneous formulation of infliximab (IFX-SC) approved to treat patients with inflammatory bowel disease may offer improved efficacy versus intravenous infliximab.Methods Patients with refractory Crohn's disease (CD, n = 32) previously treated unsuccessfully with at least 2 biologics were treated with IFX-SC and followed from baseline at Week 0 (W0) to Week 30 (W30). The study's primary endpoint was the treatment's persistence at W30, while secondary goals included the analysis of serum infliximab trough levels (TL IFX), dynamics of anti-IFX antibodies (ATIs), and clinical, serum and fecal markers of CD activity during IFX-SC treatment.Results Midterm treatment persistence with the continuation of treatment after W30 was 53%. TL IFX median values showed rapid, significant upward dynamics and exceeded 15.5 mu g/mL at W30, whereas median ATI levels significantly declined. Among ATI-negative patients at W0 (n = 15), only one showed IFX immunogenicity with newly developed ATIs at W30. Among ATI-positive patients at W0, ATI seroconversion from ATI-positive to ATI-negative status was observed in 10 of 17 patients (58.8%). Patients who had continued IFX-SC treatment at W30 showed significant decreases in C-reactive protein (P = .0341), fecal calprotectin (P = .0002), and Harvey-Bradshaw index (P = .0029) since W0.Conclusions Patients with refractory CD previously treated with at least 2 biologics exhibited clinically relevant improvement with IFX-SC, which showed less immunogenic potential than IFX-IV and highly stable TL IFX.nInfliximab is currently administered intravenously to treat Crohn's disease patients. In this study, subcutaneous administration of infliximab was found to have advantages for refractory CD patients, including stable, consistently higher levels of the drug and significantly lower immunogenicity.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30219 - Gastroenterology and hepatology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Crohns & Colitis 360
ISSN
2631-827X
e-ISSN
2631-827X
Volume of the periodical
5
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
otad040
UT code for WoS article
001100924200001
EID of the result in the Scopus database
2-s2.0-85178005189